COVID-19 Results Briefing

United Kingdom

July 2, 2021

This document contains summary information on the latest projections from the IHME model on COVID-19 in United Kingdom. The model was run on July 1, 2021 with data through June 29, 2021.

Current situation

- Daily reported cases in the last week (through June 25) increased to 12,700 per day on average compared to 8,600 the week before (Figure 1).
- Reported deaths due to COVID-19 in the last week increased to 19 per day on average compared to 12 the week before (Figure 2).
- Excess deaths due to COVID-19 in the last week increased to 19 per day on average compared to 12 the week before (Figure 2). This makes COVID-19 the number 21 cause of death in United Kingdom this week (Table 1). Estimated excess daily deaths due to COVID-19 were 1 times larger than the reported number of deaths.
- No locations had daily reported COVID-19 death rates greater than 4 per million (Figure 3).
- No locations had daily rates of excess death due to COVID-19 greater than 4 per million (Figure 3).
- We estimated that 19% of people in United Kingdom have been infected as of June 29 (Figure 5).
- Effective R, computed using cases, hospitalizations, and deaths, is greater than 1 in 4 countries (Figure 6).
- The infection-detection rate in United Kingdom was close to 79% on June 29 (Figure 7).
- Based on the GISAID and various national databases, combined with our variant spread model, we estimate the current prevalence of variants of concern (Figure 8). We estimate that B.1.351 is circulating in 1 countries, that B.1.617 is circulating in 3 countries, and that P.1 is circulating in 1 countries.

Trends in drivers of transmission

- Mobility last week was 12% lower than the pre-COVID-19 baseline (Figure 10). Mobility was near baseline (within 10%) in no countries. Mobility was lower than 30% of baseline in no locations.
- As of June 29, in the Global COVID-19 Symptom Surveys and the US COVID-19 Symptom Surveys, 50% of people self-report that they always wore a mask when leaving their home compared to 50% last week (Figure 12). Mask use was lower than 50% in England, Northern Ireland, Scotland, and Wales.
- There were 1368 diagnostic tests per 100,000 people on June 29 (Figure 14).
- In United Kingdom 85.6% of people say they would accept or would probably accept a vaccine for COVID-19. This is down by 2 percentage points from last week. The fraction of the population who are open to receiving a COVID-19 vaccine ranges from 82% in Northern Ireland to 89% in Wales (Figure 18).
- In our current reference scenario, we expect that 45.0 million people will be vaccinated by October 1 (Figure 19).
Projections

- In our reference scenario, which represents what we think is most likely to happen, our model projects 164,000 cumulative reported deaths due to COVID-19 on October 1. This represents 13,000 additional deaths from June 29 to October 1. Daily reported deaths are expected to decline until October 1, 2021 (Figure 20).

- Under our reference scenario, our model projects 165,000 cumulative excess deaths due to COVID-19 on October 1. This represents 13,000 additional deaths from June 29 to October 1. Daily excess deaths due to COVID-19 will peak at 290 on October 1, 2021 (Figure 20).

- If universal mask coverage (95%) were attained in the next week, our model projects 10,000 fewer cumulative reported deaths compared to the reference scenario on October 1.

- If universal mask coverage (95%) were attained in the next week, our model projects 10,000 fewer cumulative excess deaths due to COVID-19 compared to the reference scenario on October 1.

- Under our worse scenario, our model projects 179,000 cumulative reported deaths on October 1, an additional 15,000 deaths compared to our reference scenario. Daily reported deaths in the worse scenario are expected to decline until October 1, 2021 (Figure 20).

- Under our worse scenario, our model projects 180,000 cumulative excess deaths due to COVID-19 on October 1, an additional 15,000 deaths compared to our reference scenario. Daily excess deaths due to COVID-19 in the worse scenario are expected to decline steadily until October 1, 2021 (Figure 20).

- By October 1, we project that 4,900 lives will be saved by the projected vaccine rollout. This does not include lives saved through vaccination that has already been delivered.

- Daily infections in the reference scenario will rise to 104,890 by October 1, 2021. Under the worse scenario, daily infections will rise to 83,450 by October 1, 2021 (Figure 21).

- Figure 22 compares our reference scenario forecasts to other publicly archived models. Forecasts are widely divergent.

- At some point from June through October 1, 0 countries will have high or extreme stress on hospital beds (Figure 23). At some point from June through October 1, 0 countries will have high or extreme stress on intensive care unit (ICU) capacity (Figure 24).
Model updates

Our modeling inclusion criteria for current local transmission of a variant were updated to account for locations with relatively few sequences, but for which all sequences were collected in the last few weeks. Specifically, we consider local transmission to have potentially occurred if a location has identified more than 50 sequences of a new variant in the previous six weeks. This rule essentially only applies to P.1 and B.1.617.2.
**Figure 1.** Reported daily COVID-19 cases

![Graph showing reported daily COVID-19 cases from March 20 to July 21, with a peak in January and March 2021.](image)

**Table 1.** Ranking of excess deaths due to COVID-19 among the leading causes of mortality this week, assuming uniform deaths of non-COVID causes throughout the year

<table>
<thead>
<tr>
<th>Cause name</th>
<th>Weekly deaths</th>
<th>Ranking</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischemic heart disease</td>
<td>1,796</td>
<td>1</td>
</tr>
<tr>
<td>Stroke</td>
<td>974</td>
<td>2</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>845</td>
<td>3</td>
</tr>
<tr>
<td>Tracheal, bronchus, and lung cancer</td>
<td>824</td>
<td>4</td>
</tr>
<tr>
<td>Lower respiratory infections</td>
<td>805</td>
<td>5</td>
</tr>
<tr>
<td>Alzheimer’s disease and other dementias</td>
<td>624</td>
<td>6</td>
</tr>
<tr>
<td>Colon and rectum cancer</td>
<td>466</td>
<td>7</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>307</td>
<td>8</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>293</td>
<td>9</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>232</td>
<td>10</td>
</tr>
<tr>
<td>COVID-19</td>
<td>133</td>
<td>21</td>
</tr>
</tbody>
</table>
**Figure 2.** Smoothed trend estimate of reported daily COVID-19 deaths (blue) and total daily COVID-19 deaths (orange).
Figure 3. Daily COVID-19 death rate per 1 million on June 29, 2021

A. Daily reported COVID-19 death rate per 1 million

B. Daily excess COVID-19 death rate per 1 million
Figure 4. Cumulative COVID-19 deaths per 100,000 on June 29, 2021

A. Reported cumulative COVID-19 deaths per 100,000

B. Excess cumulative COVID-19 deaths per 100,000
Figure 5. Estimated percent of the population infected with COVID-19 on June 29, 2021

Figure 6. Mean effective R on June 18, 2021. The estimate of effective R is based on the combined analysis of deaths, case reporting, and hospitalizations where available. Current reported cases reflect infections 11-13 days prior, so estimates of effective R can only be made for the recent past. Effective R less than 1 means that transmission should decline, all other things being held the same.
Figure 7. Percent of COVID-19 infections detected. This is estimated as the ratio of reported daily COVID-19 cases to estimated daily COVID-19 infections based on the SEIR disease transmission model. Due to measurement errors in cases and testing rates, the infection-detection rate can exceed 100% at particular points in time.
Figure 8. Estimated percent of circulating SARS-CoV-2 for primary variant families on June 29, 2021.

A. Estimated percent B.1.1.7 variant

B. Estimated percent B.1.351 variant
C. Estimated percent B.1.617 variant

D. Estimated percent P.1 variant
Figure 9. Infection-fatality ratio on June 29, 2021
### Critical drivers

**Table 2. Current mandate implementation**

<table>
<thead>
<tr>
<th>Primary school closure</th>
<th>Secondary school closure</th>
<th>High school closure</th>
<th>Borders closed to any non-resident</th>
<th>Borders closed to all non-residents</th>
<th>Curfew for businesses</th>
<th>Individual curfew</th>
<th>Gathering limit: 6 indoor, 10 outdoor</th>
<th>Gathering limit: 10 indoor, 25 outdoor</th>
<th>Gathering limit: 25 indoor, 50 outdoor</th>
<th>Gathering limit: 50 indoor, 100 outdoor</th>
<th>Gathering limit: 100 indoor, 250 outdoor</th>
<th>Restaurants closed</th>
<th>Bars closed</th>
<th>Restaurants / bars closed</th>
<th>Restaurants / bars curbside only</th>
<th>Gyms, pools, other leisure closed</th>
<th>Non-essential retail closed</th>
<th>Non-essential workplaces closed</th>
<th>Stay home order</th>
<th>Stay home fine</th>
<th>Mask mandate</th>
<th>Mask mandate fine</th>
</tr>
</thead>
</table>

- **Mandate in place**
- **Mandate in place (imposed this week)**
- **Mandate in place (updated from previous reporting)**
- **No mandate**
- **No mandate (lifted this week)**
- **No mandate (updated from previous reporting)**
Figure 10. Trend in mobility as measured through smartphone app use compared to January 2020 baseline

Figure 11. Mobility level as measured through smartphone app use compared to January 2020 baseline (percent) on June 29, 2021
Figure 12. Trend in the proportion of the population reporting always wearing a mask when leaving home.

Figure 13. Proportion of the population reporting always wearing a mask when leaving home on June 29, 2021.
Figure 14. Trend in COVID-19 diagnostic tests per 100,000 people

Figure 15. COVID-19 diagnostic tests per 100,000 people on June 29, 2021
Figure 16. Increase in the risk of death due to pneumonia on February 1 compared to August 1.
Table 3. Estimates of vaccine efficacy for specific vaccines used in the model at preventing disease and infection. The SEIR model uses variant-specific estimates of vaccine efficacy at preventing symptomatic disease and at preventing infection. We use data from clinical trials directly, where available, and make estimates otherwise. More information can be found on our website.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Efficacy at preventing disease: D614G &amp; B.1.1.7</th>
<th>Efficacy at preventing infection: D614G &amp; B.1.1.7</th>
<th>Efficacy at preventing disease: B.1.351, B.1.617, &amp; P.1</th>
<th>Efficacy at preventing infection: B.1.351, B.1.617, &amp; P.1</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca</td>
<td>74%</td>
<td>52%</td>
<td>53%</td>
<td>47%</td>
</tr>
<tr>
<td>CoronaVac</td>
<td>50%</td>
<td>44%</td>
<td>40%</td>
<td>35%</td>
</tr>
<tr>
<td>Covaxin</td>
<td>78%</td>
<td>69%</td>
<td>62%</td>
<td>55%</td>
</tr>
<tr>
<td>Janssen</td>
<td>72%</td>
<td>72%</td>
<td>64%</td>
<td>56%</td>
</tr>
<tr>
<td>Moderna</td>
<td>94%</td>
<td>89%</td>
<td>83%</td>
<td>79%</td>
</tr>
<tr>
<td>Novavax</td>
<td>89%</td>
<td>79%</td>
<td>73%</td>
<td>64%</td>
</tr>
<tr>
<td>Pfizer/BioNTech</td>
<td>91%</td>
<td>86%</td>
<td>81%</td>
<td>77%</td>
</tr>
<tr>
<td>Sinopharm</td>
<td>73%</td>
<td>65%</td>
<td>47%</td>
<td>41%</td>
</tr>
<tr>
<td>Sputnik-V</td>
<td>92%</td>
<td>81%</td>
<td>73%</td>
<td>65%</td>
</tr>
<tr>
<td>Tianjin</td>
<td>66%</td>
<td>58%</td>
<td>53%</td>
<td>47%</td>
</tr>
<tr>
<td>CanSino</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other vaccines</td>
<td>75%</td>
<td>66%</td>
<td>60%</td>
<td>53%</td>
</tr>
<tr>
<td>Other vaccines (mRNA)</td>
<td>91%</td>
<td>86%</td>
<td>81%</td>
<td>77%</td>
</tr>
</tbody>
</table>
**Figure 17.** Trend in the estimated proportion of the adult (18+) population that have been vaccinated or would probably or definitely receive the COVID-19 vaccine if available.

**Figure 18.** This figure shows the estimated proportion of the adult (18+) population that has been vaccinated or would probably or definitely receive the COVID-19 vaccine if available.
Figure 19. Number of people who receive any vaccine and those who are effectively vaccinated and protected against disease, accounting for efficacy, loss to follow up for two-dose vaccines, partial immunity after one dose, and immunity after two doses.
Projections and scenarios

We produce three scenarios when projecting COVID-19. The reference scenario is our forecast of what we think is most likely to happen:

- Vaccines are distributed at the expected pace.
- Governments adapt their response by re-imposing social distancing mandates for 6 weeks whenever daily deaths reach 8 per million, unless a location has already spent at least 7 of the last 14 days with daily deaths above this rate and not yet re-imposed social distancing mandates. In this case, the scenario assumes that mandates are re-imposed when daily deaths reach 15 per million.
- Variants B.1.1.7 (first identified in the UK), B.1.351 (first identified in South Africa), and P1 (first identified in Brazil) continue to spread from locations with (a) more than 5 sequenced variants, and (b) reports of community transmission, to adjacent locations following the speed of variant scale-up observed in the regions of the United Kingdom.
- In one-quarter of those vaccinated, mobility increases toward pre-COVID-19 levels.

The worse scenario modifies the reference scenario assumptions in three ways:

- First, it assumes that variants B.1.351 or P.1 begin to spread within three weeks in adjacent locations that do not already have B.1.351 or P.1 community transmission.
- Second, it assumes that all those vaccinated increase their mobility toward pre-COVID-19 levels.
- Third, it assumes that among those vaccinated, mask use starts to decline exponentially one month after completed vaccination.

The universal masks scenario makes all the same assumptions as the reference scenario but also assumes 95% of the population wear masks in public in every location.
Figure 20. Daily COVID-19 deaths until October 01, 2021 for three scenarios

A. Reported daily COVID-19 death per 100,000

B. Excess daily COVID-19 deaths per 100,000
Figure 21. Daily COVID-19 infections until October 01, 2021 for three scenarios
Figure 22. Comparison of reference model projections with other COVID modeling groups. For this comparison, we are including projections of daily COVID-19 deaths from other modeling groups when available: Delphi from the Massachusetts Institute of Technology (Delphi), Imperial College London (Imperial), The Los Alamos National Laboratory (LANL), and the SI-KJalpha model from the University of Southern California (SIKJalpha). Daily deaths from other modeling groups are smoothed to remove inconsistencies with rounding. Regional values are aggregates from available locations in that region.
Figure 23. The estimated inpatient hospital usage is shown over time. The percent of hospital beds occupied by COVID-19 patients is color-coded based on observed quantiles of the maximum proportion of beds occupied by COVID-19 patients. Less than 5% is considered low stress, 5-9% is considered moderate stress, 10-19% is considered high stress, and 20% or greater is considered extreme stress.
Figure 24. The estimated intensive care unit (ICU) usage is shown over time. The percent of ICU beds occupied by COVID-19 patients is color-coded based on observed quantiles of the maximum proportion of ICU beds occupied by COVID-19 patients. Less than 10% is considered low stress, 10-29% is considered moderate stress, 30-59% is considered high stress, and 60% or greater is considered extreme stress.
More information

Data sources:
Mask use and vaccine confidence data are from the Global COVID-19 Symptom Survey (this research is based on survey results from University of Maryland Social Data Science Center with Facebook’s support) and the US COVID-19 Symptom Survey (this research is based on survey results from Carnegie Mellon University’s Delphi Research Group with Facebook’s support). Mask use data are also from Premise, the Kaiser Family Foundation, and the YouGov COVID-19 Behaviour Tracker survey.

Genetic sequence and metadata are primarily from the GISAID Initiative. Further details available on the COVID-19 model FAQ page.

A note of thanks:
We wish to warmly acknowledge the support of these and others who have made our COVID-19 estimation efforts possible.

More information:
For all COVID-19 resources at IHME, visit http://www.healthdata.org/covid.